- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Фаза 1B/2, многоцентровое исследование для оценки безопасности и эффективности Raludotatug DeRuxtecan с или без других противораковых исследований, у участников с высококачественным серозным эпителиальным яичником, первичной брюшной или фальтопийской трубкой, которые переработали после предыдущей химиотерапии на основе платины, первичной перитонеальной или фальтопийской трубки, которые рецидивировали после предыдущей химиотерапии на платиноме, первичной брюшины или флопии
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.
Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:
- Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
- Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread
Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
Обзор исследования
Статус
Условия
Подробное описание
This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Toll Free Number
- Номер телефона: 1-888-577-8839
- Электронная почта: Trialsites@msd.com
Места учебы
-
-
Victoria
-
St Albans, Victoria, Австралия, 3021
- Рекрутинг
- Western Health-Sunshine & Footscray Hospitals ( Site 1002)
-
Контакт:
- Study Coordinator
- Номер телефона: +61402775432
-
-
-
-
-
Haifa, Израиль, 3109601
- Рекрутинг
- Rambam Health Care Campus ( Site 0202)
-
Контакт:
- Study Coordinator
- Номер телефона: 972-4-7776234
-
Jerusalem, Израиль, 9103102
- Рекрутинг
- Shaare Zedek Medical Center ( Site 0201)
-
Контакт:
- Study Coordinator
- Номер телефона: +972-(0)2-6555424
-
Petah Tikva, Израиль, 4941492
- Рекрутинг
- Rabin Medical Center ( Site 0203)
-
Контакт:
- Study Coordinator
- Номер телефона: +97239378076
-
Ramat Gan, Израиль, 5265601
- Рекрутинг
- Sheba Medical Center ( Site 0200)
-
Контакт:
- Study Coordinator
- Номер телефона: 972-3-5304498
-
-
-
-
-
Barcelona, Испания, 08035
- Рекрутинг
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
-
Контакт:
- Study Coordinator
- Номер телефона: +349325434528607
-
Madrid, Испания, 28041
- Рекрутинг
- Hospital Universitario 12 de Octubre ( Site 0304)
-
Контакт:
- Study Coordinator
- Номер телефона: +34913908626
-
Madrid, Испания, 28040
- Рекрутинг
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
-
Контакт:
- Study Coordinator
- Номер телефона: 34915504800 x2805
-
Málaga, Испания, 29010
- Рекрутинг
- Hospital Universitario Virgen de la Victoria ( Site 0306)
-
Контакт:
- Study Coordinator
- Номер телефона: +34951032508
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08908
- Рекрутинг
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
-
Контакт:
- Study Coordinator
- Номер телефона: +34932607744
-
-
Madrid
-
Majadhonda, Madrid, Испания, 28222
- Рекрутинг
- HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
-
Контакт:
- Study Coordinator
- Номер телефона: +34 911917358
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Испания, 28027
- Рекрутинг
- Clinica Universidad de Navarra ( Site 0301)
-
Контакт:
- Study Coordinator
- Номер телефона: +349135319207513
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Испания, 46014
- Рекрутинг
- Hospital General Universitario de Valencia ( Site 0305)
-
Контакт:
- Study Coordinator
- Номер телефона: +34 963187527
-
-
-
-
Ontario
-
Toronto, Ontario, Канада, M5G 2M9
- Рекрутинг
- Princess Margaret Cancer Centre ( Site 0101)
-
Контакт:
- Study Coordinator
- Номер телефона: 416-946-2818
-
-
Quebec
-
Montreal, Quebec, Канада, H4A 3J1
- Рекрутинг
- McGill University Health Centre ( Site 0100)
-
Контакт:
- Study Coordinator
- Номер телефона: 514-934-1934x31975
-
Montreal, Quebec, Канада, H2X 0A9
- Рекрутинг
- Centre Hospitalier de l'Université de Montréal ( Site 0102)
-
Контакт:
- Study Coordinator
- Номер телефона: 514-890-8000
-
-
-
-
-
Manchester, Соединенное Королевство, M20 4BX
- Рекрутинг
- The Christie NHS Foundation Trust ( Site 0405)
-
Контакт:
- Study Coordinator
- Номер телефона: +441619187689
-
-
East Sussex
-
Brighton, East Sussex, Соединенное Королевство, BN2 1ES
- Рекрутинг
- University Hospitals Sussex NHS Foundation Trust ( Site 0404)
-
Контакт:
- Study Coordinator
- Номер телефона: +44 01273 696 955
-
-
England
-
Fulham, England, Соединенное Королевство, SW3 6JJ
- Рекрутинг
- Royal Marsden Hospital ( Site 0402)
-
Контакт:
- Study Coordinator
- Номер телефона: +442078118084
-
Sutton, England, Соединенное Королевство, SM2 5PT
- Рекрутинг
- The Royal Marsden NHS Foundation Trust. ( Site 0403)
-
Контакт:
- Study Coordinator
- Номер телефона: +442078118084
-
-
London, City of
-
London, London, City of, Соединенное Королевство, E1 1RD
- Рекрутинг
- Barts Health NHS Trust ( Site 0401)
-
Контакт:
- Study Coordinator
- Номер телефона: 020 7377 7000
-
London, London, City of, Соединенное Королевство, SE1 3SS
- Рекрутинг
- Guy s & St Thomas NHS Foundation Trust ( Site 0400)
-
Контакт:
- Study Coordinator
- Номер телефона: +44 020 7188 7188
-
-
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06510
- Рекрутинг
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
-
Контакт:
- Study Coordinator
- Номер телефона: 203-785-2404
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40202
- Рекрутинг
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
-
Контакт:
- Study Coordinator
- Номер телефона: 502-562-3429
-
-
Louisiana
-
Shreveport, Louisiana, Соединенные Штаты, 71103
- Рекрутинг
- TRIALS 365 ( Site 0020)
-
Контакт:
- Study Coordinator
- Номер телефона: 318-408-1198
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Рекрутинг
- Dana-Farber Cancer Institute ( Site 0015)
-
Контакт:
- Study Coordinator
- Номер телефона: 877-338-7425
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Рекрутинг
- Memorial Sloan Kettering Cancer Center ( Site 0003)
-
Контакт:
- Study Coordinator
- Номер телефона: 212-639-2000
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- Рекрутинг
- OU Health University of Oklahoma Medical Center ( Site 7000)
-
Контакт:
- Study Coordinator
- Номер телефона: 405-271-1112
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Рекрутинг
- Texas Oncology - DFW ( Site 8000)
-
Контакт:
- Study Coordinator
- Номер телефона: 615-329-7430
-
Houston, Texas, Соединенные Штаты, 77030
- Завершенный
- Houston Methodist Hospital ( Site 0010)
-
-
Utah
-
West Valley City, Utah, Соединенные Штаты, 84119
- Рекрутинг
- START Mountain Region ( Site 0008)
-
Контакт:
- Study Coordinator
- Номер телефона: 801-907-4750
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- Рекрутинг
- University of Virginia Health System ( Site 0011)
-
Контакт:
- Study Coordinator
- Номер телефона: 434-924-9333
-
-
-
-
-
Taipei, Тайвань, 100225
- Рекрутинг
- National Taiwan University Hospital ( Site 3001)
-
Контакт:
- Study Coordinator
- Номер телефона: +886223123456
-
Taoyuan, Тайвань, 33305
- Рекрутинг
- Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
-
Контакт:
- Study Coordinator
- Номер телефона: +88633281200
-
-
-
-
-
Sankt Gallen, Швейцария, 9000
- Рекрутинг
- HOCH Health Ostschweiz ( Site 0801)
-
Контакт:
- Study Coordinator
- Номер телефона: +41714941111
-
-
Canton of Basel-City
-
Basel, Canton of Basel-City, Швейцария, 4031
- Рекрутинг
- University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
-
Контакт:
- Study Coordinator
- Номер телефона: +41613284214
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, Швейцария, 1011
- Рекрутинг
- CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
-
Контакт:
- Study Coordinator
- Номер телефона: +41795567362
-
-
-
-
-
Seoul, Южная Корея, 03080
- Рекрутинг
- Seoul National University Hospital ( Site 2000)
-
Контакт:
- Study Coordinator
- Номер телефона: +82220723511
-
Seoul, Южная Корея, 03722
- Рекрутинг
- Severance Hospital, Yonsei University Health System ( Site 2002)
-
Контакт:
- Study Coordinator
- Номер телефона: +82222282230
-
Seoul, Южная Корея, 05505
- Рекрутинг
- Asan Medical Center ( Site 2003)
-
Контакт:
- Study Coordinator
- Номер телефона: +82230103646
-
Seoul, Южная Корея, 06351
- Рекрутинг
- Samsung Medical Center ( Site 2001)
-
Контакт:
- Study Coordinator
- Номер телефона: 82234101382
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Южная Корея, 10408
- Рекрутинг
- National Cancer Center ( Site 2004)
-
Контакт:
- Study Coordinator
- Номер телефона: 82319201760
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
- Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
- Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
- Has provided tumor tissue for biomarker research (all cohorts)
- Has an Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
- Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant
Exclusion Criteria:
- Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
- Has ≥Grade 2 peripheral neuropathy
- Has received prior treatment with cadherin-6-targeted agents
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Receives chronic steroid treatment
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)
Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Экспериментальный: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)
Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Экспериментальный: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)
Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
Экспериментальный: Cohort B-1 (R-DXd + Bevacizumab)
Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
|
|
Экспериментальный: Cohort B-2 (R-DXd RP2D + Bevacizumab)
Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
|
|
Экспериментальный: Cohort C-1 (R-DXd + Pembrolizumab)
Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Экспериментальный: Cohort D (R-DXd +/- Bevacizumab)
Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
|
|
Экспериментальный: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
|
|
Экспериментальный: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
|
|
Активный компаратор: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)
Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV injection on days 1 and 8 of each 3-week Cycle IV injection administered on Day 1 of each 4-week cycle
Другие имена:
|
|
Экспериментальный: Cohort E-1 (R-DXd + MK-2010)
Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle |
|
Экспериментальный: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)
Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles). |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
Экспериментальный: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)
Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
Экспериментальный: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)
Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease. |
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle.
Другие имена:
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Временное ограничение: Up to 21 days
|
DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Временное ограничение: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported. |
Up to approximately 3 years
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Временное ограничение: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Objective Response Rate (ORR)
Временное ограничение: Up to approximately 3 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Временное ограничение: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1: Objective Response Rate (ORR)
Временное ограничение: Up to approximately 3 years
|
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR). |
Up to approximately 3 years
|
|
Part 2: Duration of Response (DOR)
Временное ограничение: Up to approximately 3 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Временное ограничение: Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Overall Survival (OS)
Временное ограничение: Up to approximately 5 years
|
OS is defined as the time from the first dose of study treatment to death due to any cause. |
Up to approximately 5 years
|
|
Part 2: Number of Participants with One or More AEs
Временное ограничение: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Временное ограничение: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Аминокислоты, пептиды и белки
- Белки
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Углеводороды
- Циклопарафины
- Углеводороды, алициклический
- Углеводороды, циклические
- Терпена
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Координационные комплексы
- Таксииды
- Циклодеканы
- Diterpenes
- Дезоксицитидин
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Бевацизумаб
- Гемцитабин
- Карбоплатин
- Паклитаксел
- Пембролизумаб
- Липосомальный доксорубицин
- 1-додецилпиридоксаль
Другие идентификационные номера исследования
- 5909-003
- MK-5909-003 (Другой идентификатор: MSD)
- U1111-1308-2821 (Идентификатор реестра: UTN)
- 2024-514674-47-00 (Идентификатор реестра: EU CT)
- REJOICE-Ovarian02 (Другой идентификатор: MSD)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .